arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MACROGENICS INC

MGNX
$3.81 ▼ -0.31 (-7.52%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

MACROGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $242.3M
Dividend Yield
Revenue Growth 47.6%
Op. Margin -42.2%
ROIC -32.3%
FCF / Share $-0.65
Trailing P/E 12.3x
Price / Book 5.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.83M
↑ +47.6%
Net Income Profit after all expenses
$-36.77M
↑ +10.4%
Operating Margin Operating profit as % of sales
-42.2%
↑ +73.8% 5th
FCF / Share Free cash flow per share
$-0.65
↓ -14.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
6
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 58 quarters